Active not recruitingOBSERVATIONAL

Registry Platform Colorectal Cancer

This study, called AZURITE, is collecting information on how bowel cancer that has spread (metastatic colorectal cancer) is treated in Germany. It's not a trial testing a new medicine, but rather a registry that follows patients for up to three years. The aim is to understand what treatments doctors are currently choosing in their daily practice, such as chemotherapy, radiotherapy, or surgery, and how these treatments are changing over time. Researchers also want to see how these treatments affect patients' quality of life. By gathering this real-world information, doctors can learn more about the common ways this condition is managed.

At a glance

Status

Active not recruiting

Sponsor

iOMEDICO AG

Enrolment target

500

Start

01 May 2021

Estimated completion

01 Apr 2026

Colorectal Cancer Metastatic

What is this study about?

Imagine a big notebook where doctors in Germany write down how they're treating patients with bowel cancer that has spread. That's essentially what this study is – it's called AZURITE. It's not about trying out a new drug, but rather carefully observing and collecting details about the treatments already being used for metastatic colorectal cancer in everyday hospitals and clinics.

The main goal is to understand what treatments are most commonly given, how they're given, and whether these approaches change over time. When someone joins the study, information like their general health, other conditions they might have, and details about their cancer are noted down. Then, over the next three years, the study keeps track of all the different treatments they receive, such as chemotherapy, radiotherapy, or any surgeries, and how they are getting on.

This study is really important because it helps doctors and researchers get a clearer picture of how metastatic bowel cancer is being managed in the real world. By looking at a lot of patient information, they can identify patterns, see what works well for different people, and understand the journey patients go through. They're also keen to understand how treatments affect a person's general well-being and quality of life.

Key takeaways

It's an 'observational' study, meaning doctors are watching and recording, not testing a new medicine.
The study focuses on bowel cancer that has spread (metastatic colorectal cancer).
It tracks patients for up to three years to see how treatments are used in real life.
Information about your quality of life will also be collected.
Your participation helps improve understanding of cancer care for future patients.

Who may be eligible?

To be able to join this study, you would need to be 18 years old or older and have bowel cancer that has spread to other parts of your body (metastatic colorectal cancer). Importantly, you should be about to start your first round of systemic treatment for this metastatic cancer, which could include chemotherapy or other similar treatments. You would also need to be able to understand the study and agree to take part by signing a consent form.

You would not be able to join if you are not receiving any systemic treatment for your metastatic bowel cancer. Also, if your metastatic cancer had already been removed by surgery and you were only starting chemotherapy afterwards to prevent it from coming back, then this study would not be for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have bowel cancer that has spread?
Are you about to start your very first systemic treatment for this advanced bowel cancer?
Do you understand and are you able to sign a consent form?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you won't be receiving any new or experimental treatments. Instead, the study will simply record information about the treatments your doctor chooses for you as part of your usual care. This information will include details about your health when you start, your cancer, and any other health problems you might have. Over the next three years, the study will keep a record of all the systemic treatments (like chemotherapy), radiotherapy, and surgeries you receive. You will also be asked questions about your quality of life at different points during the three years. There are no extra visits or procedures beyond what your doctor would normally recommend.

Potential risks and benefits

Since this is an observational study that records your usual care, there are no direct medical risks from participating beyond those associated with your standard cancer treatments. There's also no guarantee of direct personal benefit. However, by sharing your information, you are contributing to a better understanding of metastatic bowel cancer treatments, which could help future patients. You are free to withdraw from the study at any time without affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Multiple sites all over germany
Unverified
Multiple Locations, Germany

Common questions

Is this study testing a new cancer drug?

No, this study isn't testing a new drug. It's watching and recording how current treatments for advanced bowel cancer are used in regular practice.

Will I get special treatment if I join?

No, you will receive the same care and treatments your doctor would normally recommend for you, regardless of whether you join the study.

How long will I be followed in the study?

The study will collect information about you for up to three years.

What kind of information will they collect about me?

They'll note down details about your health, your cancer, the treatments you receive (like chemotherapy or radiotherapy), and how your quality of life is.

Can I leave the study at any time?

Yes, you can decide to stop participating in the study at any point, and it won't affect your medical care.